Adherence to imatinib therapy in patients with gastrointestinal stromal tumors

Cancer Treatment Reviews

Volumn 40, Issue 2, 2014, Pages 242-247

  Blay, Jean Yves ^a   Rutkowski, Piotr ^b  

^a UNIVERSITÉ LYON 1   (France)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Adherence; Gastrointestinal stromal tumors; Imatinib

Indexed keywords

IMATINIB;

ADJUVANT THERAPY; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COST CONTROL; DIARRHEA; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MONITORING; EDEMA; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HEALTH STATUS; HEART FAILURE; HUMAN; INFECTION; INTERPERSONAL COMMUNICATION; MEDICATION COMPLIANCE; MULTIMODALITY CANCER THERAPY; NAUSEA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PATIENT EDUCATION; PHASE 3 CLINICAL TRIAL (TOPIC); PRESCRIPTION; RECURRENCE FREE SURVIVAL; REVIEW; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ADHERENCE; GASTROINTESTINAL STROMAL TUMORS; IMATINIB;

AGE FACTORS; ANTINEOPLASTIC AGENTS; BENZAMIDES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MEDICATION ADHERENCE; PIPERAZINES; POLYPHARMACY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME;

EID: 84888301994     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.07.005     Document Type: Review

References (37)

1. Blay J.Y., Bonvalot S., Casali P., et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST consensus conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005, 16:566-578.
2. Henkes M., Van der K.H., Aulitzky W.E. Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark). Ther Clin Risk Manag 2008, 4:163-187.
3. Rutkowski P., Debiec-Rychter M., Nowecki Z., et al. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. J Eur Acad Dermatol Venereol 2011, 25:264-270.
4. The ESMO/European Sarcoma Network Working Group Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(Suppl. 7):vii49-vii55.
5. Joensuu H., Trent J.C., Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev 2011, 37:75-88.
6. Blanke C.D., Demetri G.D., von Mehren M., et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008, 26:620-625.
7. Joensuu H., Eriksson M., Sundby H.K., et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012, 307:1265-1272.
8. Rutkowski P., Bylina E., Wozniak A., et al. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes. Eur J Surg Oncol 2011, 37:890-896.
9. National Comprehensive Cancer Center. NCCN clinical practice guidelines in oncology: soft tissue sarcoma V2.2012. (accessed 08.2012). http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf.
10. Reichardt P., Blay J.Y., Boukovinas I., et al. Adjuvant therapy in primary GIST: state-of-the-art. Ann Oncol 2012, 23:2776-2781.
11. Kelley R.K., Venook A.P. Nonadherence to imatinib during an economic downturn. N Engl J Med 2010, 363:596-598.
12. Streeter S.B., Schwartzberg L., Husain N., Johnsrud M. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract 2011, 7:46s-51s.
13. Tsang J., Rudychev I., Pescatore S.L. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM). J Clin Oncol 2006, 24:6119. [Meeting Abstracts].
14. Feng W., Henk H., Thomas S., et al. Compliance and persistency with imatinib. J Clin Oncol 2006, 24:6038. [Meeting Abstracts].
15. Mazzeo F., Duck L., Joosens E. Non-adherence to imatinib treatment in patients with gastro-intestinal stromal tumors (GIST): the ADAGIO study 2010. Gastrointestinal cancers symposium 2010, January 22-24, 2010; Orlando, FL, Poster 101.
16. Mazzeo F., Duck L., Joosens E., et al. Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study. Anticancer Res 2011, 31:1407-1409.
17. Blay J.Y., Le Cesne A., Ray-Coquard I., et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007, 25:1107-1113.
18. Le Cesne A., Ray-Coquard I., Bui B.N., et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 2010, 11:942-949.
19. Le Cesne A., Ray-Coquard I.L., Bui Nguyen B., et al. Time to secondary resistance (TSR) after interruption of imatinib (IM) in advanced GIST: updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival. J Clin Oncol 2011, 29(Suppl.):10015.
20. Patrikidou A., Chabaud S., Ray-Coquard I., et al. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann Oncol 2013, 24:1087-1093.
21. DeMatteo R.P., Ballman K.V., Antonescu C.R., et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373:1097-1104.
22. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364:1127-1134.
23. Halpern R., Barghout V., Zarotsky V., Williams D.E. Costs and utilization associated with imatinib adherence in patients with chronic myeloid leukemia or gastrointestinal stromal tumors. J Clin Outcomes Manage 2009, 16:215-223.
24. Sabaté E. Adherence to long-term therapies: evidence for action 2003, World Health Organization, Available at: http://apps.who.int/medicinedocs/pdf/s4883e/s4883.pdf. (accessed March 2012).
25. Hauber A.B., Gonzalez J.M., Coombs J., Sirulnik A., Palacios D., Scherzer N. Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST). Patient Prefer Adher 2011, 5:307-314.
26. Raut C.P., Morgan J.A., Quigley M.T., et al. Perioperative sunitinib dosing around extensive resections of imatinib-resistant metastatic gastrointestinal stromal tumors. J Clin Oncol 2007, 25(18S):10044. [abstract].
27. Demetri G.D., Wang Y., Wehrle E., et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 2009, 27:3141-3147.
28. Yoo C., Ryu M.H., Kang B.W., et al. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol 2010, 28:1554-1559.
29. Bui B.N., Italiano A., Miranova A., Bouchet S., Molimard M. Trough imatinib plasma levels in patients treated for advanced gastrointestinal stromal tumors evidence of large interpatient variations under treatment with standard doses. J Clin Oncol 2008, 26:10564. [Meeting Abstracts].
30. Sawaki A., Inaba K., Hayashi K., et al. Imatinib plasma concentrations during long-term effective treatment of metastatic gastrointestinal stromal tumor. J Clin Oncol 2007, 31(Suppl.):10543.
31. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med 2005, 353:487-497.
32. Sikka R., Xia F., Aubert R.E. Estimating medication persistency using administrative claims data. Am J Manag Care 2005, 11:449-457.
33. Cutrona S.L., Choudhry N.K., Fischer M.A., et al. Modes of delivery for interventions to improve cardiovascular medication adherence. Am J Manag Care 2010, 16:929-942.
34. Hill M.N., Miller N.H., Degeest S., et al. Adherence and persistence with taking medication to control high blood pressure. J Am Soc Hypertens 2011, 5:56-63.
35. Golin C.E., Liu H., Hays R.D., et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med 2002, 17:756-765.
36. de Bruin M., Viechtbauer W., Schaalma H.P., Kok G., Abraham C., Hospers H.J. Standard care impact on effects of highly active antiretroviral therapy adherence interventions: a meta-analysis of randomized controlled trials. Arch Intern Med 2010, 170:240-250.
37. Vrijens B., Vincze G., Kristanto P., Urquhart J., Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008, 336:1114-1117.